Disc Medicine (NASDAQ:IRON) Insider Rahul Khara Sells 5,000 Shares

Disc Medicine, Inc. (NASDAQ:IRON) insider Rahul Khara sold 5,000 shares of the firm’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $80.00, for a total value of $400,000.00. Following the completion of the transaction, the insider directly owned 52,324 shares in the company, valued at $4,185,920. The trade was a 8.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Rahul Khara also recently made the following trade(s):

• On Friday, June 26th, Rahul Khara sold 851 shares of Disc Medicine stock. The stock was sold at an average price of $75.00, for a total transaction of $63,825.00.
• On Monday, June 29th, Rahul Khara sold 1,649 shares of Disc Medicine stock. The stock was sold at an average price of $75.00, for a total transaction of $123,675.00.
• On Thursday, June 18th, Rahul Khara sold 7,500 shares of Disc Medicine stock. The stock was sold at an average price of $70.22, for a total transaction of $526,650.00.

Disc Medicine Stock Performance

NASDAQ IRON remained flat at $77.44 during trading hours on Friday. 307,549 shares of the company traded hands, compared to its average volume of 587,108. Disc Medicine, Inc. has a 12 month low of $40.00 and a 12 month high of $99.50. The firm has a market capitalization of $2.96 billion, a price-to-earnings ratio of -11.77 and a beta of 1.00. The company has a debt-to-equity ratio of 0.09, a current ratio of 24.14 and a quick ratio of 24.14. The stock has a 50 day simple moving average of $73.44 and a two-hundred day simple moving average of $69.73.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share for the quarter, topping the consensus estimate of ($1.71) by $0.17. On average, sell-side analysts expect that Disc Medicine, Inc. will post -6.62 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on IRON. Wall Street Zen upgraded Disc Medicine from a “sell” rating to a “hold” rating in a research report on Saturday, August 1st. HC Wainwright upped their price target on Disc Medicine from $118.00 to $120.00 and gave the stock a “buy” rating in a research report on Thursday. Morgan Stanley lifted their price objective on Disc Medicine from $80.00 to $85.00 and gave the company an “overweight” rating in a research report on Monday, June 15th. Wedbush reiterated an “outperform” rating and set a $88.00 price objective on shares of Disc Medicine in a research note on Wednesday, June 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Disc Medicine in a report on Friday, July 17th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $106.00.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in Disc Medicine in the 2nd quarter worth $180,502,000. Deutsche Bank AG purchased a new position in shares of Disc Medicine in the second quarter valued at about $2,241,000. Bank of New York Mellon Corp purchased a new position in shares of Disc Medicine in the second quarter valued at about $14,974,000. State of Wyoming bought a new position in shares of Disc Medicine in the second quarter worth about $25,000. Finally, GSA Capital Partners LLP bought a new position in shares of Disc Medicine in the second quarter worth about $1,194,000. Institutional investors own 83.70% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.